Advertisement

The ASCO Post Newsreels help clinicians stay up to date on news in the world of clinical oncology and hematology. Newsreels feature leading authorities presenting high-impact clinical findings at major oncology meetings throughout the year.



Showing All Recent Newsreels Videos


Advertisement

AACR Annual Meeting 2022

John B.A.G. Haanen, MD, PhD, on Solid Tumors: Early Study Results on CAR T Cells and the CARVac Vaccine Strategy

Yaqi Zhao, MSc, on ALL: Molecular Profile and Efficacy of Inotuzumab Ozogamicin

Alana L. Welm, PhD, on Metastatic Outgrowth in the Lungs: Identifying a New Immune-Mediated Pathway

Josh Neman, PhD, on Brain Metastasis: A Neuroscience Perspective

Benoit You, MD, PhD, on Endometrial Cancer: New Data on Combining Olaparib, Cyclophosphamide, and Metformin

Vivek Subbiah, MD, on Designing Clinical Trials for Precision Oncology

Ari M. VanderWalde, MD, MPH, MBioeth, on Melanoma: New Data on Ipilimumab and Nivolumab

Klaus Pantel, MD, on Liquid Biopsy Research: Opportunities and Challenges

Patricia M. LoRusso, DO, on Targeting KRAS: Clinical Successes and Challenges

Tina Cascone, MD, PhD, on NSCLC: New Findings From the NeoCOAST Trial on Durvalumab-Based Therapy

Silvia C. Formenti, MD, on Adapting Radiation Therapy to Immune Checkpoint Blockade

Iván Márquez-Rodas, MD, PhD, on Advanced Melanoma: Efficacy of Intratumoral BO-112 With Systemic Pembrolizumab

Meenakshi Anurag, PhD, on Breast Cancer: New Data on Combining Anastrozole and Fulvestrant

Electra D. Paskett, PhD, on Social Stresses and Cancer Treatment: An Expert Perspective

Maria Elena Martinez, PhD, MPH, on Colorectal Cancer Screening in Underserved Populations: COVID, Silver Linings, and Challenges Ahead

Nicolas Girard, MD, PhD, on NSCLC: New Data on Event-Free Survival With Nivolumab Plus Platinum-Doublet Chemotherapy

Gautam Mehta, MD, on Precision Oncology: An Overview of the Accelerated Approval Program

Jia Luo, MD, on NSCLC: Clinicopathologic and Molecular Characterization of KRAS G12D–Mutated Disease

David A. Barbie, MD, on Mesothelioma: Activating the STING Pathway May Promote Antitumor Immunity

Zev Wainberg, MD, on Gastroesophageal Junction Adenocarcinoma: Early Results With Anti-CD39 Antibody Plus Chemoimmunotherapy

Cheryl L. Willman, MD, on Cancer Genomic Sequencing in Tribal Nations of the American Southwest

Marcia R. Cruz-Correa, MD, PhD, on a Vision for the Future of Cancer Research and Treatment

Lillian L. Siu, MD, on Looking Toward the Future of Clinical Research and Clinical Trials

Gulam A. Manji, MD, PhD, on Gastric and Gastroesophageal Junction Adenocarcinomas: New Data on Pembrolizumab Plus Capecitabine and Oxaliplatin

Timothy A. Yap, MBBS, PhD, on Advanced Solid Tumors With DNA Damage Response Defects: Early Data on Elimusertib

Timothy A. Yap, MBBS, PhD, on Developing Novel Therapeutic Strategies to Target DNA Damage Response in the Clinic

Timothy A. Yap, MBBS, PhD, on Ovarian, Breast, Pancreatic, and Prostate Cancers With Genetic Mutations: A First-in-Human Trial of AZD5305

Priscilla K. Brastianos, MD, on CNS Metastases: Understanding Their Evolution and the Clinical Implications

Charles L. Sawyers, MD, on Transforming Patient Outcomes: The Future of Cancer Research

Christine A. Iacobuzio-Donahue, MD, PhD, on Pancreatic Cancer: Novel Insights Into Genetics and Evolution

Nickolas Papadopoulos, PhD, on Multicancer Early Detection: Opportunities and Challenges

Matthew L. Meyerson, MD, PhD, on Lung Adenocarcinoma: Somatic Mutations, Germline Risk, and Ancestry


NCCN 2022 Annual Conference

Julio M. Pow-Sang, MD, on Nonmetastatic Prostate Cancer: Update on Best Management Practices

Margaret A. Tempero, MD, on Pancreatic Adenocarcinoma: Emerging Systemic Therapy Options

Thomas W. Flaig, MD, on Bladder Cancer: New Treatment Options

Reid M. Ness, MD, MPH, on Colorectal Cancer: Updates in Screening Recommendations

Genevieve Boland, MD, PhD, on Advanced Melanoma: Best Management Practices

Ann S. LaCasce, MD, MMSc, on Relapsed/Refractory Indolent Follicular Lymphoma: Management Updates

Maria Alma Rodriguez, MD, on Vaccinations for Patients With Cancer and Cancer Survivors

Smitha S. Krishnamurthi, MD, on Colorectal Cancer: Treatment Updates


SGO 2022 Annual Meeting on Women’s Cancer

Ursula A. Matulonis, MD, on Ovarian Cancer: New Data on Mirvetuximab Soravtansine

Pedro T. Ramirez, MD, on Hysterectomy for Early Cervical Cancer: New Findings on Open vs Minimally Invasive Surgery


2022 Multidisciplinary Head and Neck Cancers Symposium

Phillip Pifer, MD, PhD, on Head and Neck Squamous Cell Carcinoma: New Data on Focal Adhesion Kinase

Glenn J. Hanna, MD, on Oropharyngeal Squamous Cell Carcinoma: Detecting Occult Recurrence

Nancy Lee, MD: Toward Personalization of Radiotherapy for HPV-Related Oropharyngeal Carcinoma

Peter Zeng, MD/PhD Candidate: Immune Cell Signature Predicts Survival in HPV-Associated Head and Neck Cancer

David S. Hong, MD, on New Findings on Tisotumab Vedotin-tftv in Patients With Head and Neck Squamous Cell Carcinoma

Michelle Mierzwa, MD, on Oropharyngeal Cancer: Early Results on De-escalated Radiotherapy

Elizabeth D. Cash, PhD, on Addressing the Psychological Aspects of Head and Neck Cancer

Sue S. Yom, MD, PhD, on Thyroid Cancer: Expert Perspective on the State of the Field


2022 ASCO Genitourinary Cancers Symposium

Matthew R. Zibelman, MD, on Renal Cell Carcinoma: New Results on Combination of Nivolumab and Axitinib

Hielke-Martijn de Vries, MD, on Penile Cancer: New Data on Atezolizumab and Radiotherapy

Alfredo Berruti, MD, on Adrenocortical Carcinoma: Preliminary Study Results With Adjuvant Mitotane

Daniel P. Petrylak, MD, on Bladder Cancer: Study EV-103 Cohort H Findings on Enfortumab Vedotin-ejfv

Axel Bex, MD, PhD, on Renal Cell Carcinoma: New Findings From the NeoAvAx Trial on Avelumab and Axitinib

Fred Saad, MD, on Prostate Cancer: Results From the PROpel Trial on Olaparib and Abiraterone

Axel S. Merseburger, MD, on Prostate Cancer: New Data From the PRESIDE Trial on Enzalutamide, Docetaxel, and Prednisolone

Simon J. Crabb, PhD, MBBS, on Urothelial Carcinoma: Switch Maintenance Therapy With Rucaparib Following Chemotherapy

Wesley Yip, MD, on Urothelial Carcinoma: New Data on Neoadjuvant Gemcitabine and Cisplatin

Karen E. Knudsen, PhD, MBA, on Addressing Disparities in Genitourinary Cancers

Karim Fizazi, MD, PhD, on Prostate Cancer: Early Results From the CYPIDES Trial of ODM-208

Kim Nguyen Chi, MD, on Prostate Cancer: New Findings on Niraparib, Abiraterone, and Prednisone

Jonathan E. Rosenberg, MD, on Urothelial Cancer: New Conclusions About Durvalumab Plus Olaparib

Toni K. Choueiri, MD, on Renal Cell Carcinoma: Follow-up Data on Pembrolizumab

Massimo Di Maio, MD, on Urothelial Cancer: Data on Niraparib and Best Supportive Care as Maintenance Therapy

Alicia K. Morgans, MD, MPH, on Prostate Cancer: Profiles of Patients and Their Journeys

Petros Grivas, MD, PhD, on Urothelial Cancer: New Data on Sacituzumab Govitecan-hziy and Pembrolizumab

Sumanta K. Pal, MD, on Advances in Genitourinary Cancer Treatment: Expert Perspective

Neil E. Fleshner, MD, MPH, on High-Risk Prostate Cancer: New Data on Abiraterone and Cabazitaxel

Tanya B. Dorff, MD, on Prostate Cancer: Early Data on PSCA-Targeted CAR T-Cell Therapy

Xin Gao, MD, on Prostate Cancer: Early-Phase Results on Bavdegalutamide

Matthew R. Smith, PhD, MD, on Prostate Cancer: Phase III Data on Darolutamide, Androgen Deprivation, and Docetaxel


2021 Multidisciplinary Thoracic Cancers Symposium

Julia Rotow, MD, on Patient Selection in Treating Thoracic Cancers: Looking to Driver Mutations and Biomarkers

Carolyn Presley, MD, on Dementia in Patients Treated for Thoracic Cancer

Pranshu Mohindra, MD, MBBS, on NSCLC: Benefits of Intensity-Modulated Proton Therapy–Based Reirradiation

Mirek Fatyga, PhD, on NSCLC: New Data on Stereotactic Body Radiotherapy vs Conventionally Fractionated Radiotherapy

Narjust Duma, MD, on Advanced NSCLC: Reducing Racial Disparities in Outcomes

Ara Klijian, MD, on Lung Cancer: Operability in Patients With Poor Pulmonary Function


2022 ASCO Gastrointestinal Cancers Symposium

Kohei Shitara, MD, on Gastric and Esophageal Cancers: Long-Term Follow-up on Nivolumab Plus Chemotherapy

Yu Sunakawa, MD, PhD, on Gastric Cancer: Predicting Treatment-Related Toxicities With Biomarkers

Heinz-Josef Lenz, MD, on Colorectal Cancer: Update From the CheckMate 9X8 Trial on Nivolumab, mFOLFOX6, and Bevacizumab

Nilofer Saba Azad, MD, on Novel Treatment Combinations Under Study in Biliary Tract Cancers

Ghassan K. Abou-Alfa, MD, MBA, on Hepatocellular Carcinoma: Open-Label Trial of Tremelimumab and Durvalumab

Tanios S. Bekaii-Saab, MD, on Pancreatic and Other Tumors With KRAS G12C Mutation: Updated Data on Use of Adagrasib

Afsaneh Barzi, MD, PhD, on Colorectal Cancer: Early Data on Regorafenib and Pembrolizumab

Zev A. Wainberg, MD, on Gastric or Gastroesophageal Junction Adenocarcinoma: Follow-up Data on Pembrolizumab and Chemotherapy

Francesca Battaglin, MD, on Upper GI Cancers and the Potential Value of Recurrent Neoantigens

Anthony B. El-Khoueiry, MD, on Hepatocellular Carcinoma: Expert Perspective on Novel Additive Strategies

Gabriel A. Brooks, MPH, MD, on Colorectal Cancer: Expert Perspective on the Need to Deintensify Oxaliplatin

Van K. Morris, MD, on Metastatic Colorectal Cancer: Early Trial Results on Encorafenib, Cetuximab, and Nivolumab

Melissa Amy Lumish, MD, on Rectal Cancer: PD-1 Blockade for Mismatch Repair–Deficient Disease

Romain Cohen, MD, PhD, on Metastatic Colorectal Cancer: Long-Term Follow-up on Nivolumab Plus Ipilimumab

Thierry André, MD, on Esophagogastric Adenocarcinoma: New Findings on Nivolumab and Ipilimumab


2021 ASH Annual Meeting & Exposition

Paolo Ghia, MD, PhD, on CLL: New Data on Treatment With Ibrutinib Plus Venetoclax

L. Elizabeth Budde, MD, PhD, on Relapsed/Refractory Follicular Lymphoma: Early Results on Mosunetuzumab Monotherapy

Daniel A. Ermann, MD, on DLBCL: Outcomes With Consolidative Radiation Therapy

Talha Badar, MD, on TP53-Mutated AML and the Impact of Allogeneic Stem Cell Transplantation on Survival

Tarek H. Mouhieddine, MD, on Relapsed/Refractory Multiple Myeloma and Bispecific Antibodies

Masayuki Umeda, MD, on Pediatric AML: Identifying a Key Subtype-Defining Lesion

Carsten Utoft Niemann, MD, PhD, on CLL: Time-Limited Venetoclax and Ibrutinib for Patients With Relapsed or Refractory Disease

Michael R. Bishop, MD, on Aggressive B-Cell NHL: Tisagenlecleucel vs Standard of Care as Second-Line Therapy

Roni Shouval, MD, PhD, on TP53-Mutant Large B-Cell Lymphoma and CAR T-Cell Therapy

Eunice S. Wang, MD, on FLT3-Mutated AML: Gilteritinib and Azacitidine for Intensive Induction Chemotherapy–Ineligible Patients

Leslie S. Kean, MD, PhD, on Bone Marrow Transplantation: Using Abatacept to Prevent Graft-vs-Host Disease

Alba Rodriguez-Meira, DPhil, on TP53-Mutated Leukemic Transformation in Myeloproliferative Neoplasms

Andrew Matthews, MD, on AML: CPX-351 vs Venetoclax/Azacitidine for Initial Therapy

Sangeetha Venugopal, MD, on Secondary AML: Impact of Front-Line Treatment Approach

Nikhil C. Munshi, MD, PhD, on COVID-19 Vaccine Effectiveness in Patients With Multiple Myeloma

Joe Schroers-Martin, MD, on Follicular Lymphoma: Precursor Mutations May Be Detectable Years Before Diagnosis

Manali Kamdar, MD, on Large B-Cell Lymphoma: Lisocabtagene Maraleucel vs the Standard of Care

Musa Yilmaz, MD, on FLT3-ITD–Mutated AML: Findings on Quizartinib With Decitabine and Venetoclax

Anil Aktas-Samur, PhD, on Identifying Low-Risk Smoldering Multiple Myeloma

Romanos Sklavenitis-Pistofidis, MD, on Smoldering Myeloma: Identifying Biomarkers of Response to Immunotherapy

Tycel Phillips, MD, on Marginal Zone Lymphoma: Efficacy and Safety of Parsaclisib

Matthew S. Davids, MD, on Younger Patients With CLL: Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy


2021 San Antonio Breast Cancer Symposium

Peter Schmid, MD, PhD, on Early-Stage Triple-Negative Breast Cancer: Neoadjuvant Treatment With Pembrolizumab and Chemotherapy

Kevin Kalinsky, MD, on HR-Positive HER2-Negative Breast Cancer: Endocrine Therapy and Chemotherapy

Javier Cortés, MD, PhD, on Previously Untreated Triple-Negative Breast Cancer: Pembrolizumab Plus Chemotherapy

François-Clément Bidard, MD, PhD, on Metastatic Breast Cancer: Endocrine Therapy and Palbociclib

Michael Gnant, MD, on HR-Positive, HER2-Negative Early Breast Cancer: Trial Results With Palbociclib Treatment

Komal Jhaveri, MD, on Triple-Negative and Metastatic Breast Cancers: New Data on Neratinib, Fulvestrant, and Trastuzumab

Patricia A. Ganz, MD, on Early Breast Cancer, Olaparib, Chemotherapy, and Quality of Life

Charles Coombes, MD, PhD, on Hormone Receptor–Positive HER2-Negative Breast Cancer: Use of Samuraciclib Plus Fulvestrant

Lisa A. Carey, MD, on HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies

Ann H. Partridge, MD, MPH, on SABCS Meeting Highlights: Expert Perspective

Banu Arun, MD, on Fine-Tuning Risk Assessment and Risk Reduction in Breast Cancer

Elizabeth A. Mittendorf, MD, PhD, on Making Strides in Managing Triple-Negative Breast Cancer

Meredith M. Regan, ScD, on Early Breast Cancer: Updated Results From the TEXT and SOFT Trials

Sara A. Hurvitz, MD, on HER2-Positive Metastatic Breast Cancer: T-DXd vs T-DM1


SITC 2021

Stephanie T. Schmidt, PhD, on NSCLC: The Immunomodulatory Impact of Neoadjuvant Chemotherapy and Immune-Based Treatments

Kim A. Reiss, MD, on HER2-Overexpressing Solid Tumors: First-in-Human Study of Anti-HER2 CAR Macrophages

Emily Z. Keung, MD, on Interactions of Sarcoma, Immune Infiltrates, and Checkpoint Blockade

Yuki Muroyama, MD, PhD, on A Novel Marker of Clinical Response to PD-1 Blockade Under Study

Hans Wildiers, MD, on Metastatic Breast Cancer: Comparing Addition of Eftilagimod Alpha vs Placebo to Paclitaxel

Hannah E. Dzimitrowicz, MD, on COVID-19 Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors

John M. Kirkwood, MD, on Melanoma: Early Study Results on Vidutolimod and Pembrolizumab

Jeffrey Weber, MD, PhD, on Coronavirus, Cancer, and Immunotherapy: Navigating Clinical Trials and Treatment

Sean Khozin, MD, MPH, on Delivering Precision Cancer Care in the Era of Digital Medicine

Patrick Hwu, MD, and Mary Dean, JD, CAE, on What’s Ahead for Cancer Immunology and SITC

Lynda Chin, MD, on the Landscape and Future of Digital Medicine

Mehmet Altan, MD, on Solid Tumors: Interim Safety and Efficacy Results on NKTR-255 Plus Cetuximab

Yevgeniy R. Semenov, MD, on Cutaneous Immune-Related Adverse Events and Response to Immune Checkpoint Inhibitors


NCCN 2021 Virtual Congress: Hematologic Malignancies

Alice S. Mims, MD, on AML: Updates on Managing Newly Diagnosed Disease

Jennifer A. Woyach, MD, on CLL/SLL: Using Minimal Residual Disease Assessment in Clinical Practice

Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: How Many Drugs Are Enough?

Ronald S. Go, MD, on Managing Histiocytic Neoplasms: New NCCN Guidelines


2021 ASTRO Annual Meeting

Robert A. Olson, MD, on Oligometastases: New Data on Stereotactic Ablative Radiotherapy

Diana D. Shi, MD, on IDH-Mutant Gliomas: De Novo Pyrmidine Synthesis Inhibitor Under Study

David A. Palma, MD, PhD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs Surgery

Youssef Zeidan, MD, PhD, on HER2-Positive Breast Cancer: Treatment-Related Cardiotoxicity

Aadel A. Chaudhuri, MD, PhD, on Personalizing Treatment for Oligometastatic Cancer

C. Jillian Tsai, MD, PhD, on Using Radiotherapy to Thwart Tumor Growth in Advanced Cancers

Daniel J. Ma, MD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Comparing Longer and Shorter Courses of Radiotherapy

Benjamin Movsas, MD, on Prostate Cancer: Patient-Reported Outcomes on Radiotherapy and Androgen Suppression

Mark K. Buyyounouski, MD, MS, on Prostate Cancer: Hypofractionated vs Conventional Radiotherapy After Surgery

Karen M. Winkfield, MD, PhD, on Digital Health to Improve Patient Outcomes and Experience

Matthew Manning, MD, on Resolving Racial Disparities in the Treatment of Breast and Lung Cancers

Amar U. Kishan, MD, on Prostate Cancer: Impact of Androgen-Deprivation Therapy With Radiotherapy

Erin Murphy, MD, on Low-Grade Glioma: Neurocognitive Function Following Treatment

Shauna Campbell, DO, on Head and Neck Cancer: Toxicity Associated With Hypofractionated IMRT

Daniel F. Hayes, MD, on Liquid Biopsies to Detect and Monitor Oligometastases

Howard M. Sandler, MD, on Prostate Cancer Highlights: An Expert Perspective

Yongbae Kim, MD, on Elective Internal Mammary Node Irradiation in Women With Node-Positive Breast Cancer: Results of a Randomized Phase III Trial


2021 ASCO Quality Care Symposium

Tina Shih, PhD, on Trends in Total and Out-of-Pocket Costs of Cancer Care

Manali I. Patel, MD, MPH, on Community-Based Intervention and Cancer Care Disparity

Leticia Nogueira, PhD, MPH, on the Association of Medicaid Expansion and Early Mortality Following Lung Cancer Surgery

Sarah S. Mougalian, MD, on a Next-Day Access Program for Patients With Cancer

Benjamin W. Corn, MD, on Integrating Hope Into Clinical Oncology

Courtney Williams, DrPH, on Cancer Survivors: Working Together to Improve Patient Adherence

Divya A. Parikh, MD, on Improving Care Documentation With a Patient Conversation Guide

Divya Gupta, MD, on Improving Advance Care Planning Conversations With Patients

John V. Cox, DO, MBA, on Reshaping Practice Models to Better Care for Patients With Cancer

Jenny Jing Xiang, MD, on Improving Clinical Trial Recruitment With a Universal Prescreening Protocol

Aakash Desai, MPH, MD, on the Precision Oncology Promise: Can We Deliver?

Katherine E. Reeder-Hayes, MD, MBA, on Geography, Breast Cancer Treatment, and Racial Disparities

Morgan R.L. Lichtenstein, MD, on Insurance Plan, Prior Authorization, and Time to Receipt of Oral Anticancer Drugs


ESMO Congress 2021

Helena M. Earl, MBBS, PhD, on HER2-Positive Early Breast Cancer: A Meta-analysis of Trastuzumab Trials

Nicoletta Colombo, MD, on Cervical Cancer: KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy

Javier Cortés, MD, PhD, on HER2-Positive Breast Cancer: Trastuzumab Deruxtecan vs Trastuzumab Emtansine

Jason J. Luke, MD, on Melanoma: KEYNOTE-716 Trial of Pembrolizumab vs Placebo

Gabriel N. Hortobagyi, MD, on Advanced Breast Cancer Treated With Endocrine Therapy and Ribociclib

Toni K. Choueiri, MD, on Renal Cell Carcinoma: Quality-of-Life Data From KEYNOTE-564 on Pembrolizumab vs Placebo

Naveen S. Vasudev, PhD, MBChB, on RCC: Changing the Dosing Schedule of Ipilimumab Plus Nivolumab

Gerhardt Attard, MD, PhD, on Prostate Cancer: Abiraterone and Prednisolone in the STAMPEDE Protocol

Karim Fizazi, MD, PhD, on Prostate Cancer: Newly Reported Survival Rates With Abiraterone, Docetaxel, and Prednisone

Benjamin Besse, MD, PhD, on NSCLC: A Vaccine Under Study to Treat Advanced Disease

Robin Cornelissen, MD, PhD, on HER2 Exon 20–Mutated NSCLC: Poziotinib in Treatment-Naive Disease

Jenny F. Seligmann, MBChB, PhD, on Colorectal Cancer: Adavosertib Compared With Active Monitoring

Jonathan Lim, MBBS, MRCP: The Future of the Oncology Workforce Since the COVID-19 Pandemic

Joseph M. Unger, PhD, on the Impact of NCI-Sponsored Treatment Trials

Thomas Powles, MD, PhD, on Urothelial Carcinoma: Erdafitinib, Cetrelimab, and FGFR Alterations

Neeraj Agarwal, MD, on Advanced Prostate Cancer: Data on Cabozantinib Plus Atezolizumab

Filippo Pietrantonio, MD, and Federica Morano, MD, on Colorectal Cancer and the MAYA Trial Strategy: Temozolomide, Ipilimumab, and Nivolumab

Dieter Hörsch, MD: For Patients With Bronchopulmonary Neuroendocrine Tumors, Lanreotide Autogel May Be Beneficial

Susana N. Banerjee, MBBS, PhD, on Ovarian, Fallopian Tube, or Primary Peritoneal Adenocarcinoma: Treatment Findings From the EORTC-1508 Trial

Susana N. Banerjee, MBBS, PhD, on Ovarian Cancer: Novel Combination Therapy Under Study

Hope S. Rugo, MD, on Triple-Negative Breast Cancer: Treatment Findings From KEYNOTE-355 on Pembrolizumab and Chemotherapy


SOHO 2021

Curtis Lachowiez, MD, on AML: Venetoclax Combined With FLAG-IDA

Saad Z. Usmani, MBA, MD, on Multiple Myeloma: Updated Results From the CARTITUDE-1 Study of Ciltacabtagene Autoleucel

Kieron M. Dunleavy, MD: Update on Primary Mediastinal B-Cell Lymphoma

Luis E. Aguirre, MD, on Chronic Myelomonocytic Leukemia: Keys to Assessment and Treatment


IASLC 2021 World Conference on Lung Cancer

Matthew Smeltzer, PhD, on International Lung Cancer Clinical Trials: The Impact of COVID-19

Alex A. Adjei, MD, PhD, on Disparities in Lung Cancer Care: The Global Burden

Christine D. Berg, MD, on Lung Cancer Deaths Attributable to Air Pollution: Global Variability

Jamie L. Studts, PhD, on The Stigma of Lung Cancer: It’s Time to Eliminate It

Prasad S. Adusumilli, MD, on CAR T-Cell Therapy for Mesothelioma

Nasser K. Altorki, MD, on NSCLC: Adjuvant Atezolizumab for Stage IB–IIIA Disease


2021 Pan Pacific Lymphoma Conference

Peihua (Peggy) Lu, MD, on CAR T-Cell Therapy: Research in China

David S. Kroll, MD, on Recognizing and Treating Depression and Anxiety in Patients With Lymphoma

Jared E. Matya, PharmD, BCOP, on Supportive Therapies for Side Effects Related to Novel Oral Treatments

Andrew D. Zelenetz, MD, PhD, on MRD Testing in the Management of Non-Hodgkin Lymphoma

Jonathan W. Friedberg, MD, on Managing Indolent NHL With Oral Therapies

Alexey V. Danilov, MD, PhD, on Lymphoid Malignancies: Novel Agents Targeting BTK Inhibitor–Resistant Disease

Alison J. Moskowitz, MD, on ABVD in Hodgkin Lymphoma: Adding Brentuximab Vedotin and Checkpoint Inhibitors to Standard Treatment

Bruce D. Cheson, MD, and Stephen M. Ansell, MD, PhD, on Non-Hodgkin and Follicular Lymphomas: Integrating Non–CAR T-Based Treatments

Sonali M. Smith, MD: Can CNS Prophylaxis Prevent Secondary High-Grade B-Cell Lymphomas?

James O. Armitage, MD, on Advanced Hodgkin Lymphoma: Choosing Among BEACOPP, A-AVD, and Checkpoint Inhibitors

Steven M. Horwitz, MD, on Advanced-Stage Mycosis Fungoides and Sezary Syndrome: Update on Management Practices

Nina Shah, MD, on Newly Diagnosed Multiple Myeloma: Novel Combination Therapies

Muhamed Baljevic, MD, on Multiple Myeloma: Review of Novel Management Strategies


EHA 2021 Virtual Congress

Efstathios Kastritis, MD, on Amyloidosis: Standard of Care Plus Daratumumab

Keith W. Pratz, MD, on AML: Venetoclax, Azacitidine, and Disease Response

Arnon P. Kater, MD, PhD, on CLL: Fixed-Duration Ibrutinib and Venetoclax vs Chlorambucil Plus Obinutuzumab

Gaurav Goyal, MD, on DLBCL: Comparing R-CHOP and R-EPOCH for Overall Survival Benefits

Martin Kaiser, MD, on Myeloma and Plasma Cell Leukemia: Transplantation Plus Daratumumab/CVRD Therapy

Philippe Moreau, MD, on Newly Diagnosed Multiple Myeloma: Daratumumab Maintenance vs Observation

Martin Hutchings, MD, PhD, on Hodgkin Lymphoma: Brentuximab Vedotin With Chemotherapy

Claire Harrison, MD, DM, on Myelofibrosis: Fedratinib as First-Line Therapy After Prior Ruxolitinib

Ruben A. Mesa, MD, on Myelofibrosis, Transfusion Independence, and Momelotinib

Cristina Gasparetto, MD, on Multiple Myeloma: Selinexor, Carfilzomib, and Dexamethasone in Carfilzomib-Nonrefractory Patients

Martin H. Dreyling, MD, PhD, on Follicular Lymphoma: Safety and Efficacy of Tisagenlecleucel

Advertisement

Advertisement



May
27
Today In Oncology
Race/Ethnicity and Poverty Are Associated With Worse Outcomes Among Children With High-Risk Neuroblastoma
Study Finds State Public Welfare Spending Was Associated With Improved 5-Year Overall Survival in Black Patients With Cancer
Nearly Half of Black Patients With Metastatic Breast Cancer Report Not Being Informed About Clinical Trials
Use of Telemedicine for Cancer Care Increased During the COVID-19 Pandemic, but Varied by Race, Socioeconomic Status, and Other Factors
Multiple Myeloma: Treatment Conundrums
View More 
Advertisement
© 2022 HSP News Service, L.L.C.
Designed by Harborside